 The FDA has instituted a clinical hold on Legend Biotech Corporations NASDAQ: LEGN Phase 1 trial for LB1901. LB1901 is the companys investigational autologous chimeric antigen receptor T-cell CAR-T therapy targeting malignant CD4 T-cells for relapsed or refractory T-cell lymphoma TCL. 